AYHAN CELIK

Prof. Dr. AYHAN CELIK

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2021 in Micromachines
Verified
Journal Article
Open access
PDF file
MAMuhammet Avcil
Muhammet Avcil
ACAYHAN CELIK
AYHAN CELIK
In recent years, an innovative transdermal delivery technology has attracted great interest for its ability to distribute therapeutics and cosmeceuticals for several applications, including vaccines, drugs, and biomolecules for skin-related problems. The advantages of microneedle patch technology have been extensively evaluated in the latest literature; hence, the academic publications in this area are rising exponentially. Like all new technologies, the microneedle patch application has great potential but is not without limitations. In this review, we will discuss the possible limitations by highlighting the areas where a great deal of improvements are required. Emphasising these concerns early on should help scientists and technologists to address the matters in a timely fashion and to use their resources wisely.

1 December 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
GRGareth A. Roberts
Gareth A. Roberts
ACAYHAN CELIK
AYHAN CELIK
DHDominic J.B. Hunter
Dominic J.B. Hunter
TOTobias W.B. Ost
Tobias W.B. Ost
JWJohn H. White
John H. White
SFSabine L. Flitsch
Sabine L. Flitsch
P450 RhF from Rhodococcus sp. NCIMB 9784 is the first example of a new class of cytochrome p450 in which electrons are supplied by a novel, FMN- and Fe/S-containing, reductase partner in a fused arrangement. We have previously cloned the gene encoding the enzyme and shown it to comprise an N-terminal p450 domain fused to a reductase domain that displays similarity to the phthalate family of oxygenase reductase proteins. A reductase of this type had never previously been reported to interact with a cytochrome p450. In this report we describe the purification and partial characterization of p450 RhF. We show that the enzyme is self-sufficient in catalyzing the O-dealkylation of 7-ethoxycoumarin. The p450 RhF catalyzed O-dealkylation of 7-ethoxycoumarin is inhibited by several compounds that are known inhibitors of cytochrome p450. Presteady state kinetic analysis indicates that p450 RhF shows a 500-fold preference for NAPDH over NADH in terms of Kd value (6.6 microm versus 3.7 mm, respectively). Potentiometric studies show reduction potentials of -243 mV for the two-electron reduction of the FMN and -423 mV for the heme (in the absence of substrate).

1 January 2014 in Journal of Biotechnology
Verified
Journal Article
Closed access
SBStamatia Bellou
Stamatia Bellou
AMAnna Makri
Anna Makri
Dimitris SarrisDimitris Sarris
Dimitris Sarris
KMKonstantinos Michos
Konstantinos Michos
PRPenelope Rentoumi
Penelope Rentoumi
George AggelisGeorge Aggelis
George Aggelis

28 May 2019 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
PDF file
MAMuhammet Avcil
Muhammet Avcil
GAGokhan Akman
Gokhan Akman
JKJens Klokkers
Jens Klokkers
DJDohyeon Jeong
Dohyeon Jeong
ACAYHAN CELIK
AYHAN CELIK

1 June 2012 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
ACAYHAN CELIK
AYHAN CELIK
GYGülden Yetiş
Gülden Yetiş

7 July 2005 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
ACAYHAN CELIK
AYHAN CELIK
SFSabine L. Flitsch
Sabine L. Flitsch
NTNicholas J. Turner
Nicholas J. Turner
The hydroxylation of α-ionone 1 and β-ionone 2 to their corresponding mono-hydroxylated derivatives has been examined using a recombinant E. coli whole cell system, in which cytochromes P450 SU1 and SU2, and P450 SOY were over-expressed with their cognate ferrodoxins. Both substrates are hydroxylated with a high degree of regioselectivity and for α-ionone 1 the reaction is highly diastereoselective yielding the anti-isomer.